U.S., Aug. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07125222) titled 'Use of Gocovri to Improve Disability Due to Radiation Encephalopathy' on Aug. 08.
Brief Summary: A study to assess the effect of Gocovri (extended-release amantidine) to improve disability as assessed by the disability rating scale (DRS) and cognition as assessed by the Montreal Cognitive Assessment (MoCA) test in patients with radiation encephalopathy.
Study Start Date: Sept., 2025
Study Type: INTERVENTIONAL
Condition:
Radiation Encephalopathy
Intervention:
DRUG: Gocovri (extended-release amantidine)
Gocovri is extended release formulation of amantidine. Starting on Day 1, patients will start Gocovri 137mg daily. If there is...